bristol-myers glp-1 receptor agonist products Updated evidence on cardiovascular and renal effects of agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology S-1/A
Description
The relative ranking of the different treatment was estimated for each outcome using p-score [22]
However, concerns have been expressed regarding their safety profile
However, gastrointestinal symptoms are the main reason why patients decide to end treatment
Oberbauer R, Krivanek P, Turnheim K
correspondingly [90]
Boland BS, Edelman SV, Wolosin JD
